- Home
- SRZN vs EPIX Comparison
SRZN vs EPIX Comparison
Compare SRZN & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- EPIX
- Stock Information
- Founded
- SRZN 2015
- EPIX 2009
- Country
- SRZN United States
- EPIX Canada
- Employees
- SRZN N/A
- EPIX N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- EPIX Health Care
- Exchange
- SRZN Nasdaq
- EPIX Nasdaq
- Market Cap
- SRZN 72.8M
- EPIX 75.9M
- IPO Year
- SRZN N/A
- EPIX N/A
- Fundamental
- Price
- SRZN $8.71
- EPIX $1.72
- Analyst Decision
- SRZN Strong Buy
- EPIX Hold
- Analyst Count
- SRZN 2
- EPIX 3
- Target Price
- SRZN $38.50
- EPIX $2.00
- AVG Volume (30 Days)
- SRZN 22.6K
- EPIX 53.1K
- Earning Date
- SRZN 08-11-2025
- EPIX 08-04-2025
- Dividend Yield
- SRZN N/A
- EPIX N/A
- EPS Growth
- SRZN N/A
- EPIX N/A
- EPS
- SRZN N/A
- EPIX N/A
- Revenue
- SRZN $11,638,000.00
- EPIX N/A
- Revenue This Year
- SRZN N/A
- EPIX N/A
- Revenue Next Year
- SRZN N/A
- EPIX N/A
- P/E Ratio
- SRZN N/A
- EPIX N/A
- Revenue Growth
- SRZN N/A
- EPIX N/A
- 52 Week Low
- SRZN $5.90
- EPIX $1.40
- 52 Week High
- SRZN $18.17
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- SRZN 47.45
- EPIX 51.31
- Support Level
- SRZN $8.00
- EPIX $1.68
- Resistance Level
- SRZN $8.94
- EPIX $1.75
- Average True Range (ATR)
- SRZN 0.72
- EPIX 0.04
- MACD
- SRZN -0.07
- EPIX 0.00
- Stochastic Oscillator
- SRZN 27.14
- EPIX 62.50
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.